PRNewsWire
01 Jun 2026, 00:00 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/d3-bio-presents-first-line-data-for-elisrasib-d3s-001-at-asco-2026-next-generation-kras-g12c-inhibitor-shows-landmark-efficacy-in-untreated-nsclc-302786434.html
Read source
Search tags
Story key points
3 claims · impact-rated
Elisrasib monotherapy achieved a 78.0% overall response rate (ORR) and a median progression-free survival (PFS) of 12.4 months in first-line KRAS G12C–mutant NSCLC. — High efficacy in a first-line setting for a difficult-to-treat mutation is a primary catalyst for biotech valuation and potential market leadership.
+0.80Elisrasib in combination with pembrolizumab showed an ORR of 81.3% and a 12-month PFS rate of 53.7% in first-line KRAS G12C–mutant NSCLC. — Strong combination data expands the drug's potential utility and commercial reach, though the impact is slightly lower than the breakthrough monotherapy data.
+0.70Elisrasib monotherapy demonstrated a favorable safety profile with Grade 3 or higher treatment-related adverse events (TRAEs) occurring in only 7% of patients. — Low toxicity increases the probability of regulatory approval and clinical adoption over existing, more toxic standards of care.
+0.50Ticker attribution
Continue reading
6 related stories
Model heads
Pembrolizumab (Keytruda) showed strong efficacy in combination with elisrasib, supporting its continued use as a benchmark in NSCLC treatment.
No ticker relationship head found.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
1d ago
